Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon elects Dennis Fenton to board

This article was originally published in Scrip

Executive Summary

Dendreon, a biotech company developing therapeutics to treat cancer, has appointed Dennis Fenton to its board of directors. Dr Fenton has 30 years' experience of the pharmaceutical and biotech industries, including over two decades at Amgen where he most recently served as executive vice-president for operations and compliance officer until 2008. He is currently a board member of Genelux, Napo Pharmaceuticals, Kythera Biopharmaceuticals and XenoPort.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015179

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel